CY71 Stock Overview
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Anixa Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.90 |
| 52 Week High | US$4.66 |
| 52 Week Low | US$2.58 |
| Beta | 0.87 |
| 1 Month Change | -13.69% |
| 3 Month Change | -34.09% |
| 1 Year Change | -34.39% |
| 3 Year Change | -25.26% |
| 5 Year Change | -22.75% |
| Change since IPO | -20.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| CY71 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -5.1% | -2.0% |
| 1Y | -34.4% | -21.1% | -0.3% |
Return vs Industry: CY71 underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: CY71 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| CY71 volatility | |
|---|---|
| CY71 Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CY71's share price has been volatile over the past 3 months.
Volatility Over Time: CY71's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 5 | Amit Kumar | www.anixa.com |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.
Anixa Biosciences, Inc. Fundamentals Summary
| CY71 fundamental statistics | |
|---|---|
| Market cap | €93.44m |
| Earnings (TTM) | -€10.09m |
| Revenue (TTM) | €197.15k |
457.2x
P/S Ratio-8.9x
P/E RatioIs CY71 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CY71 income statement (TTM) | |
|---|---|
| Revenue | US$210.00k |
| Cost of Revenue | US$161.00k |
| Gross Profit | US$49.00k |
| Other Expenses | US$10.79m |
| Earnings | -US$10.74m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 23.33% |
| Net Profit Margin | -5,116.19% |
| Debt/Equity Ratio | 0% |
How did CY71 perform over the long term?
See historical performance and comparison